STOCK TITAN
  1. Home
  2. News
  3. DRTSW

Alpha Tau Medical Ltd. Warrant - $DRTSW STOCK NEWS

Welcome to our dedicated page for Alpha Tau Medical Ltd. Warrant news (Ticker: $DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Warrant stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Tau Medical Ltd. Warrant's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Tau Medical Ltd. Warrant's position in the market.

News
Alpha Tau to Participate in November Investor Conferences
Rhea-AI Summary
Alpha Tau Medical Ltd. announced that it will participate in several investor conferences in November 2023, including the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
-
News
Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility
Rhea-AI Summary
Alpha Tau Medical Ltd. has entered into a long-term lease agreement for a standalone building in Hudson, New Hampshire, to establish its second U.S. manufacturing site. The new site will be larger than the existing site in Lawrence, Massachusetts, and is expected to support the company's goals of scaling up capacity and achieving manufacturing redundancy. The company plans to initiate manufacturing of Alpha DaRT treatments at the Hudson facility within two years, with a capacity of nearly 1.8 million Alpha DaRT sources per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News
Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board
Rhea-AI Summary
Alpha Tau Medical announces that former FDA Commissioner Dr. Stephen M. Hahn has joined its Scientific Advisory Board. Dr. Hahn's expertise will be valuable as the company advances its Alpha DaRT technology towards FDA clearance and explores new indications for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
management
News
Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel’s Hadassah Medical Center
Rhea-AI Summary
Alpha Tau Medical announces successful treatment of patient with advanced inoperable pancreatic cancer using Alpha DaRT therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Alpha Tau Medical reports positive outcomes in feasibility trials and receives land grant for future headquarters
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
earnings
-
News
Alpha Tau Medical to Participate in September Investor Conferences
Rhea-AI Summary
Alpha Tau Medical Ltd. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences
News
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
Rhea-AI Summary
Initial long-term safety and tumor control outcomes for patients treated with Alpha DaRT showed 89% complete response rate and 77% two-year local recurrence-free survival rate. No grade 3 or higher acute or late toxicities observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
clinical trial
-
News
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announces that Raphi Levy, Chief Financial Officer, will present at the Emerging Growth Conference on August 9th, 2023, to discuss the innovative alpha-radiation cancer therapy Alpha DaRT™. The event will take place virtually, with an archived webcast available for those unable to attend live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences acquisition
-
News
Alpha Tau Medical to Participate in June Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
conferences
News
Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
earnings
Stock DRTSW logo
Alpha Tau Medical Ltd. Warrant

Nasdaq:DRTSW

DRTSW Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

DRTSW Stock Data

51.74M
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Jerusalem

About DRTSW

alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.